Blueprint Medicines Co. (NASDAQ:BPMC) COO Sells $250,458.36 in Stock

Blueprint Medicines Co. (NASDAQ:BPMC) COO Christina Rossi sold 2,274 shares of the stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $110.14, for a total transaction of $250,458.36. Following the sale, the chief operating officer now directly owns 67,109 shares in the company, valued at $7,391,385.26. This trade represents a 3.28 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Christina Rossi also recently made the following trade(s):

• On Wednesday, December 18th, Christina Rossi sold 2,274 shares of Blueprint Medicines stock. The shares were sold at an average price of $95.91, for a total transaction of $218,099.34.
• On Wednesday, November 27th, Christina Rossi sold 2,274 shares of Blueprint Medicines stock. The shares were sold at an average price of $95.10, for a total transaction of $216,257.40.

Blueprint Medicines Trading Down 0.6 %

Shares of NASDAQ:BPMC opened at $114.91 on Friday. Blueprint Medicines Co. has a 12 month low of $72.24 and a 12 month high of $121.90. The company has a quick ratio of 3.27, a current ratio of 3.32 and a debt-to-equity ratio of 1.09. The company’s fifty day simple moving average is $95.80 and its 200 day simple moving average is $95.33. The firm has a market cap of $7.30 billion, a price-to-earnings ratio of -54.46 and a beta of 0.61.

Blueprint Medicines (NASDAQ:BPMC) last issued its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported ($0.89) EPS for the quarter, topping analysts’ consensus estimates of ($0.97) by $0.08. Blueprint Medicines had a negative net margin of 29.48% and a negative return on equity of 112.30%. The business had revenue of $128.20 million for the quarter, compared to analyst estimates of $127.56 million. During the same period last year, the business posted ($2.20) earnings per share. The firm’s quarterly revenue was up 126.5% on a year-over-year basis. As a group, research analysts forecast that Blueprint Medicines Co. will post -3.67 EPS for the current fiscal year.

Institutional Investors Weigh In On Blueprint Medicines

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Jennison Associates LLC acquired a new stake in Blueprint Medicines in the 4th quarter valued at $31,417,000. China Universal Asset Management Co. Ltd. increased its stake in Blueprint Medicines by 10.6% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 13,470 shares of the biotechnology company’s stock valued at $1,175,000 after buying an additional 1,287 shares during the last quarter. R Squared Ltd acquired a new stake in Blueprint Medicines in the 4th quarter valued at $51,000. KBC Group NV increased its stake in Blueprint Medicines by 63.9% in the 4th quarter. KBC Group NV now owns 2,625 shares of the biotechnology company’s stock valued at $229,000 after buying an additional 1,023 shares during the last quarter. Finally, Fifth Third Bancorp increased its stake in Blueprint Medicines by 207.5% in the 4th quarter. Fifth Third Bancorp now owns 3,075 shares of the biotechnology company’s stock valued at $268,000 after buying an additional 2,075 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the stock. StockNews.com raised shares of Blueprint Medicines from a “sell” rating to a “hold” rating in a research note on Friday, November 8th. Wells Fargo & Company reduced their price objective on shares of Blueprint Medicines from $153.00 to $151.00 and set an “overweight” rating on the stock in a research note on Thursday, October 31st. JPMorgan Chase & Co. assumed coverage on shares of Blueprint Medicines in a research note on Thursday, November 14th. They issued an “overweight” rating and a $126.00 price objective on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $135.00 price objective on shares of Blueprint Medicines in a research note on Friday, November 15th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $124.00 price objective (down from $135.00) on shares of Blueprint Medicines in a research note on Monday, January 13th. One research analyst has rated the stock with a sell rating, seven have given a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $122.72.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.